Lactoferrin in the preterm infants' diet attenuates iron-induced oxidation products.
Free radical injury is thought to play a significant role in the pathogenesis of several disease processes in low birth weight premature infants including retinopathy of prematurity and necrotizing enterocolitis. Because iron is a known catalyst in free radical-mediated oxidation reactions, the objectives of the present in vitro studies were to determine whether after exposure to air 1) iron present in infant formula, or that added to human milk or formula as medicinal iron or as iron contained in human milk fortifier, increases free radical and lipid peroxidation products; and 2) recombinant human lactoferrin added to formula or human milk attenuates iron-mediated free radical formation and lipid peroxidation. Before adding medicinal iron to formula and human milk, significantly more ascorbate and alpha-hydroxyethyl radical production and more lipid peroxidation products (i.e. thiobarbituric acid reactive substances, malondialdehyde, and ethane) were observed in formula. After the addition of medicinal iron to either formula or human milk, further increases were observed in free radical and lipid peroxidation products. When iron-containing human milk fortifier was added to human milk, free radicals also increased. In contrast, the addition of apo-recombinant human lactoferrin to formula or human milk decreased the levels of oxidative products when medicinal iron or human milk fortifier was present. We speculate that the presence of greater concentration of iron and the absence of lactoferrin in formula compared with human milk results in greater in vitro generation of free radicals and lipid peroxidation products. Whether iron-containing formula with lactoferrin administered enterally to preterm infants will result in less free radical generation in vivo has yet to be established.
Raghuveer
Talkad S
TS
Department of Pediatrics, The University of Iowa, Iowa City, Iowa 52242, USA. traghuveer@kumc.edu
McGuire
Erin M
EM
Martin
Sean M
SM
Wagner
Brett A
BA
Rebouché
Charles J
CJ
Buettner
Garry R
GR
Widness
John A
JA
D001059:Apoproteins / Q000008:administration & dosage; D005609:Free Radicals / Q000009:adverse effects / Q000032:analysis; D006801:Humans; D007225:Infant Food / Q000009:adverse effects* / Q000032:analysis; D007231:Infant, Newborn; D007234:Infant, Premature; D007501:Iron / Q000009:adverse effects*; D007781:Lactoferrin / Q000008:administration & dosage*; D015227:Lipid Peroxidation; D008895:Milk, Human / Q000737:chemistry; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011994:Recombinant Proteins / Q000008:administration & dosage
D001059:Apoproteins; D005609:Free Radicals; D011994:Recombinant Proteins; C039223:apolactoferrin; D007501:Iron; D007781:Lactoferrin